Functional Mitral Regurgitation An Interventional Cardiologist’s Perspective

Lowie M.R. van Assche; Mark J. Ricciardi

doi:10.1097/CRD.0000000000000219

Functional Mitral Regurgitation An Interventional Cardiologist’s Perspective

Lowie M.R. van Assche, Mark J. Ricciardi^*

^*Corresponding author for this work

Medicine, Cardiology Division

Research output: Contribution to journal › Review article › peer-review

3 Scopus citations

Abstract

Functional mitral regurgitation (FMR) is common in patients with heart failure and portends a poor prognosis. The etiology is secondary to nonischemic or ischemic (postmyocardial infarction) adverse remodeling. Treatment includes guideline-directed medical therapy, cardiac resynchronization therapy, and in some cases, surgical repair or replacement. Transcatheter mitral valve (MV) repair with the MitraClip device is approved in patients with degenerative MR and is currently under investigation for use in FMR, as are several transcatheter MV replacement devices. This review discusses the basis of FMR pathophysiology, classification, and prognosis; provides an overview of current therapeutic approaches; examines the available literature on the use of MitraClip in patients with FMR; and provides insight into ongoing clinical trials and new investigational devices for the treatment of FMR.

Original language	English (US)
Pages (from-to)	230-238
Number of pages	9
Journal	Cardiology in review
Volume	26
Issue number	5
DOIs	https://doi.org/10.1097/CRD.0000000000000219
State	Published - Sep 1 2018

Keywords

Functional
MitraClip
Mitral regurgitation

ASJC Scopus subject areas

General Medicine

Access to Document

10.1097/CRD.0000000000000219

Cite this

@article{bbc41ec54f1b4e5c857a2d81cb8750e9,

title = "Functional Mitral Regurgitation An Interventional Cardiologist{\textquoteright}s Perspective",

abstract = "Functional mitral regurgitation (FMR) is common in patients with heart failure and portends a poor prognosis. The etiology is secondary to nonischemic or ischemic (postmyocardial infarction) adverse remodeling. Treatment includes guideline-directed medical therapy, cardiac resynchronization therapy, and in some cases, surgical repair or replacement. Transcatheter mitral valve (MV) repair with the MitraClip device is approved in patients with degenerative MR and is currently under investigation for use in FMR, as are several transcatheter MV replacement devices. This review discusses the basis of FMR pathophysiology, classification, and prognosis; provides an overview of current therapeutic approaches; examines the available literature on the use of MitraClip in patients with FMR; and provides insight into ongoing clinical trials and new investigational devices for the treatment of FMR.",

keywords = "Functional, MitraClip, Mitral regurgitation",

author = "{van Assche}, {Lowie M.R.} and Ricciardi, {Mark J.}",

year = "2018",

month = sep,

day = "1",

doi = "10.1097/CRD.0000000000000219",

language = "English (US)",

volume = "26",

pages = "230--238",

journal = "Cardiology in review",

issn = "1061-5377",

publisher = "Lippincott Williams and Wilkins Ltd.",

number = "5",

}

TY - JOUR

T1 - Functional Mitral Regurgitation An Interventional Cardiologist’s Perspective

AU - van Assche, Lowie M.R.

AU - Ricciardi, Mark J.

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Functional mitral regurgitation (FMR) is common in patients with heart failure and portends a poor prognosis. The etiology is secondary to nonischemic or ischemic (postmyocardial infarction) adverse remodeling. Treatment includes guideline-directed medical therapy, cardiac resynchronization therapy, and in some cases, surgical repair or replacement. Transcatheter mitral valve (MV) repair with the MitraClip device is approved in patients with degenerative MR and is currently under investigation for use in FMR, as are several transcatheter MV replacement devices. This review discusses the basis of FMR pathophysiology, classification, and prognosis; provides an overview of current therapeutic approaches; examines the available literature on the use of MitraClip in patients with FMR; and provides insight into ongoing clinical trials and new investigational devices for the treatment of FMR.

AB - Functional mitral regurgitation (FMR) is common in patients with heart failure and portends a poor prognosis. The etiology is secondary to nonischemic or ischemic (postmyocardial infarction) adverse remodeling. Treatment includes guideline-directed medical therapy, cardiac resynchronization therapy, and in some cases, surgical repair or replacement. Transcatheter mitral valve (MV) repair with the MitraClip device is approved in patients with degenerative MR and is currently under investigation for use in FMR, as are several transcatheter MV replacement devices. This review discusses the basis of FMR pathophysiology, classification, and prognosis; provides an overview of current therapeutic approaches; examines the available literature on the use of MitraClip in patients with FMR; and provides insight into ongoing clinical trials and new investigational devices for the treatment of FMR.

KW - Functional

KW - MitraClip

KW - Mitral regurgitation

UR - http://www.scopus.com/inward/record.url?scp=85056518270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056518270&partnerID=8YFLogxK

U2 - 10.1097/CRD.0000000000000219

DO - 10.1097/CRD.0000000000000219

M3 - Review article

C2 - 29939849

AN - SCOPUS:85056518270

SN - 1061-5377

VL - 26

SP - 230

EP - 238

JO - Cardiology in review

JF - Cardiology in review

IS - 5

ER -

Functional Mitral Regurgitation An Interventional Cardiologist’s Perspective

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this